CompletedPhase 4NCT02878564
Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
Studying Schistosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Toronto
- Principal Investigator
- Rupert Kaul, MD/PhDUniversity of Toronto
- Intervention
- Praziquantel(drug)
- Enrollment
- 34 enrolled
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2016 – 2016
Study locations (1)
- UVRI-IAVI HIV Vaccine program, Entebbe, Wakiso, Uganda
Collaborators
UVRI-IAVI HIV Vaccine Program, Uganda
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02878564 on ClinicalTrials.govOther trials for Schistosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06698510Introduction of Arpraziquantel Treatment for Schistosomiasis Control in Preschool-aged Children in Endemic Areas: A Small-scale Public Health Intervention StudyPeter Steinmann
- RECRUITINGNANCT06873308Assessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic SchistosomiasisIRCCS Sacro Cuore Don Calabria di Negrar